Is Trident Lifeline overvalued or undervalued?

As of 26 September 2025, Trident Lifeline's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued based on its financial ratios, with a PE ratio of 21.47, an EV to EBITDA of 16.28, and a Price to Book Value of 6.88. These figures suggest that investors are paying a premium for the stock relative to its earnings and book value.
When compared to peers, Trident Lifeline's valuation stands out as particularly high. For instance, Sun Pharma has a PE ratio of 33.18, while Cipla is at 22.45, both of which are lower than Trident Lifeline's ratio. Additionally, the PEG ratio of 0.26 indicates that the stock may not be justified by its growth prospects, especially when compared to peers like Divi's Lab, which has a PEG of 1.74. Despite a recent positive performance against the Sensex, with a 1-week return of 2.24% compared to the Sensex's -2.66%, the overall valuation metrics suggest that Trident Lifeline is overvalued in the current market environment.